Lexington Biosciences Inc. (LXGTF)

[StockBro75]

Yeah a bit frustrating, but also it just might mean that there is nothing new to report yet. They have already told us that they hired Diablo to do the clinicals and back in November already we learned that they took delivery of the first models for test purposes from the manufacturer. The last PR assured us they had the funds to complete the tests via conversion of the warrants. We know that average time to market for a cardivascular device in the FDA 510K accelerated path program is 6 months. So we know that good news is coming. But it just might mean nothing new to share this week.